Switch theme
Sign up to access all valuation multiples
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
2020
869
LTM Revenue $660M
LTM EBITDA $191M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wuxi XDC has a last 12-month revenue of $660M and a last 12-month EBITDA of $191M.
In the most recent fiscal year, Wuxi XDC achieved revenue of $273M and an EBITDA of $54.0M.
Wuxi XDC expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wuxi XDC valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $127M | $273M | XXX | XXX | XXX |
| Gross Profit | $14.6M | $33.6M | XXX | XXX | XXX |
| Gross Margin | 11% | 12% | XXX | XXX | XXX |
| EBITDA | $29.5M | $54.0M | XXX | XXX | XXX |
| EBITDA Margin | 23% | 20% | XXX | XXX | XXX |
| Net Profit | $7.1M | $20.0M | XXX | XXX | XXX |
| Net Margin | 6% | 7% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Wuxi XDC's stock price is HKD 35 (or $5).
Wuxi XDC has current market cap of HKD 42.4B (or $5.5B), and EV of HKD 38.7B (or $5.0B).
See Wuxi XDC trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $5.5B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Wuxi XDC has market cap of $5.5B and EV of $5.0B.
Wuxi XDC's trades at 8.1x LTM EV/Revenue multiple, and 28.0x LTM EBITDA.
Analysts estimate Wuxi XDC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Wuxi XDC and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 18.2x | XXX | XXX | XXX |
| EV/EBITDA | 92.2x | XXX | XXX | XXX |
| P/E | 149.6x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | -187.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpWuxi XDC's NTM/LTM revenue growth is 35%
Wuxi XDC's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $23K for the same period.
Over next 12 months, Wuxi XDC's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Wuxi XDC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Wuxi XDC and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 114% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 83% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $23K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 7% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi XDC acquired XXX companies to date.
Last acquisition by Wuxi XDC was XXXXXXXX, XXXXX XXXXX XXXXXX . Wuxi XDC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Wuxi XDC founded? | Wuxi XDC was founded in 2020. |
| Where is Wuxi XDC headquartered? | Wuxi XDC is headquartered in Hong Kong. |
| How many employees does Wuxi XDC have? | As of today, Wuxi XDC has 869 employees. |
| Who is the CEO of Wuxi XDC? | Wuxi XDC's CEO is Dr. Jincai Li. |
| Is Wuxi XDC publicy listed? | Yes, Wuxi XDC is a public company listed on HKG. |
| What is the stock symbol of Wuxi XDC? | Wuxi XDC trades under 02268 ticker. |
| When did Wuxi XDC go public? | Wuxi XDC went public in 2023. |
| Who are competitors of Wuxi XDC? | Similar companies to Wuxi XDC include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Wuxi XDC? | Wuxi XDC's current market cap is $5.5B |
| What is the current revenue of Wuxi XDC? | Wuxi XDC's last 12-month revenue is $660M. |
| What is the current EBITDA of Wuxi XDC? | Wuxi XDC's last 12-month EBITDA is $191M. |
| What is the current EV/Revenue multiple of Wuxi XDC? | Current revenue multiple of Wuxi XDC is 8.1x. |
| What is the current EV/EBITDA multiple of Wuxi XDC? | Current EBITDA multiple of Wuxi XDC is 28.0x. |
| What is the current revenue growth of Wuxi XDC? | Wuxi XDC revenue growth between 2023 and 2024 was 114%. |
| Is Wuxi XDC profitable? | Yes, Wuxi XDC is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
